Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005633 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

A Phase 1 study of Melanoma (Skin), sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00005633 is a Phase 1 study of Melanoma (Skin) that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005633, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Conditions Studied

Melanoma (Skin)

Interventions

  • BIOLOGICAL OVA BiP peptide
  • BIOLOGICAL gp209-2M antigen
  • BIOLOGICAL recombinant 70-kD heat-shock protein
  • BIOLOGICAL tyrosinase peptide

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Start Date 1999-06
Est. Completion 2002-06
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005633

The ClinicalTrials.gov registry entry for NCT00005633 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 4 interventions - of which OVA BiP peptide is the first listed.

NCT00005633 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00005633 about?

NCT00005633 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

What is the current status of trial NCT00005633?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-06. Estimated completion is 2002-06.

What conditions does trial NCT00005633 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT00005633?

The interventions under investigation include: OVA BiP peptide (BIOLOGICAL), gp209-2M antigen (BIOLOGICAL), recombinant 70-kD heat-shock protein (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).

Who is sponsoring clinical trial NCT00005633?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005633 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma (Skin)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.